Tecentriq® (atezolizumab): A new identified risk of severe cutaneous adverse reactions

A Dear Healthcare Professional Letter has been issued by Hoffman-La Roche to update healthcare professionals on a new identified risk of severe cutaneous adverse reactions (SCARs) associated with the use of Tecentriq®. Based on the totality of evidence in a recent analysis, SCARs are now considered to be an identified risk for atezolizumab. Consequently, the local Tecentriq® package insert will be updated to reflect the safety information on this risk. Healthcare professionals are advised to refer suspected cases of SCARs to a dermatologist for further diagnosis and management, to withhold atezolizumab from patients with suspected Stevens Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and to permanently withdraw atezolizumab for any grade confirmed SJS or TEN. Caution is advised when considering the use of atezolizumab in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Nov 2020

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.moh.gov.sg/hpp/, and follow the procedures below to access the MOH Alert system.

Step 1: On the top navigation ribbon of webpage, select 'For Healthcare Professionals' followed by 'Health Professionals Portal' and click on the choice of profession. User will be redirected to the specific HPP webpage for the selected profession.

Step 2: Click on the Restricted Content icon on the left panel of webpage and login via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’ section

Step 4: Click on the Drug Alert tab to view the DHCPLs.